Intervention

Mepolizumab 100 MG

ClinicalTrials.gov intervention label

Clinical trials7

Recruiting0

Common conditions9

Lead sponsors shown7

Clinical trials

7 shown

Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic AsthmaNCT06069310 · 2023-09-01

ACTIVE_NOT_RECRUITING

Immunological Basis for Mepolizumab Activity in COPDNCT05320939 · 2023-04-01

Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).NCT05365841 · 2022-05-15

A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPDNCT05138250 · 2022-05-08

Severe Asthma Exacerbations and Mepolizumab TreatmentNCT04914078 · 2021-09-21

Effect of Mepolizumab on Severe Eosinophilic AsthmaNCT04641741 · 2021-04-01

Use of Nucala in Severe AsthmaNCT05441059 · 2021-01-01

Common conditions

COPD2 Asthma1 Asthma Severe Persistent Uncontrolled1 Chronic Rhinosinusitis With Nasal Polyps1 Chronic Rhinosinusitis Without Nasal Polyps1 Eosinophilic Asthma1 Severe Asthma1 Severe Eosinophilic Asthma1 Severe Eosinophilic Asthma w/wo CRSwNP1

Leading sponsors

Frisius Medisch Centrum1 Hospital Clinico Universitario de Santiago1 National and Kapodistrian University of Athens1 Sheffield Teaching Hospitals NHS Foundation Trust1 Temple University1 Università degli Studi di Ferrara1 University of Crete1

Trial status mix

UNKNOWN4

COMPLETED2

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE21

PHASE31

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.